OBJECTIVE: To assess the abilities of cisplatin, paclitaxel, and flexible heteroarotinoid (Flex-Het) compound (SHetA2) to sensitize ovarian cancer cells to induction of the extrinsic apoptosis pathway by death receptor ligands, tumor necrosis factor alpha (TNFalpha), and TNF-related apoptosis-inducing ligand (TRAIL). STUDY DESIGN: The effects of various combinations of TNFalpha, TRAIL, cisplatin, paclitaxel, and SHetA2 on viability and apoptosis in two established ovarian cancer cell lines, A2780 and SK-OV-3, and normal human primary endometrial cultures were measured with a cytotoxicity assay, flow cytometric analysis of annexin-V, and propidium iodide staining and Western blot analysis of caspase 8 and 3 activation. RESULTS: Ovarian cancer and normal cells were resistant to TNFalpha and TRAIL. Cisplatin and paclitaxel did not increase sensitivity to these agents in either cell type. In contrast, combination of SHetA2 with TNFalpha or TRAIL induced a synergistic induction of apoptosis in cancer cells that involved activation of the extrinsic pathway caspase 8 and executioner caspase 3. The TRAIL combination was more potent than the TNFalpha combination. SHetA2 did not harm the viability of normal cells as a single agent or in combination with the death receptor ligands. CONCLUSIONS: SHetA2, but not cisplatin or paclitaxel, can overcome resistance of ovarian cancer cells to TNFalpha and TRAIL without increasing sensitivity of normal cells to these death receptor ligands.
OBJECTIVE: To assess the abilities of cisplatin, paclitaxel, and flexible heteroarotinoid (Flex-Het) compound (SHetA2) to sensitize ovarian cancer cells to induction of the extrinsic apoptosis pathway by death receptor ligands, tumor necrosis factor alpha (TNFalpha), and TNF-related apoptosis-inducing ligand (TRAIL). STUDY DESIGN: The effects of various combinations of TNFalpha, TRAIL, cisplatin, paclitaxel, and SHetA2 on viability and apoptosis in two established ovarian cancer cell lines, A2780 and SK-OV-3, and normal human primary endometrial cultures were measured with a cytotoxicity assay, flow cytometric analysis of annexin-V, and propidium iodide staining and Western blot analysis of caspase 8 and 3 activation. RESULTS:Ovarian cancer and normal cells were resistant to TNFalpha and TRAIL. Cisplatin and paclitaxel did not increase sensitivity to these agents in either cell type. In contrast, combination of SHetA2 with TNFalpha or TRAIL induced a synergistic induction of apoptosis in cancer cells that involved activation of the extrinsic pathway caspase 8 and executioner caspase 3. The TRAIL combination was more potent than the TNFalpha combination. SHetA2 did not harm the viability of normal cells as a single agent or in combination with the death receptor ligands. CONCLUSIONS: SHetA2, but not cisplatin or paclitaxel, can overcome resistance of ovarian cancer cells to TNFalpha and TRAIL without increasing sensitivity of normal cells to these death receptor ligands.
Authors: Doris M Benbrook; Scott A Kamelle; Suresh B Guruswamy; Stan A Lightfoot; Teresa L Rutledge; Natalie S Gould; Bethany N Hannafon; S Terence Dunn; K Darrell Berlin Journal: Invest New Drugs Date: 2005-10 Impact factor: 3.850
Authors: S Guruswamy; S Lightfoot; M A Gold; R Hassan; K D Berlin; R T Ivey; D M Benbrook Journal: J Natl Cancer Inst Date: 2001-04-04 Impact factor: 13.506
Authors: Mijin Kim; Jessica Liao; Melissa L Dowling; K Ranh Voong; Sharon E Parker; Shulin Wang; Wafik S El-Deiry; Gary D Kao Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: C N A M Oldenhuis; J H Stegehuis; A M E Walenkamp; S de Jong; E G E de Vries Journal: Curr Opin Pharmacol Date: 2008-07-28 Impact factor: 5.547
Authors: S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks Journal: Science Date: 1994-11-04 Impact factor: 47.728
Authors: Shengquan Liu; Chad W Brown; K Darrell Berlin; Aridam Dhar; Suresh Guruswamy; David Brown; Ginger J Gardner; Michael J Birrer; Doris M Benbrook Journal: J Med Chem Date: 2004-02-12 Impact factor: 7.446
Authors: Robert C Young; Mark F Brady; Roberta K Nieberg; Harry J Long; Allan R Mayer; Samuel S Lentz; Jean Hurteau; David S Alberts Journal: J Clin Oncol Date: 2003-12-01 Impact factor: 44.544
Authors: Jenny M Whitworth; Angelina I Londoño-Joshi; Jeffrey C Sellers; Patsy J Oliver; Donald D Muccio; Venkatram R Atigadda; J Michael Straughn; Donald J Buchsbaum Journal: Gynecol Oncol Date: 2011-12-09 Impact factor: 5.482
Authors: Doris Mangiaracina Benbrook; Baskar Nammalwar; Andrew Long; Hiroyuki Matsumoto; Anil Singh; Richard A Bunce; K Darrell Berlin Journal: Invest New Drugs Date: 2013-11-20 Impact factor: 3.850